Study Subject Medical center
Item
st. jude participants:
boolean
C0681850 (UMLS CUI [1,1])
C0565990 (UMLS CUI [1,2])
Mature B-Cell Lymphoma WHO tumor classification | Burkitt Lymphoma | Atypical Burkitt's lymphoma | Diffuse Large B-Cell Lymphoma | Mediastinal (Thymic) Large B-Cell Lymphoma | Mature B-Cell Lymphoma NOS
Item
1. participant must have a histologic diagnosis of a mature b cell lymphoma (e.g., burkitt lymphoma/leukemia, atypical burkitt lymphoma, diffuse large b-cell lymphoma, mediastinal large b-cell lymphoma, mature b-cell lymphoma nos) as defined in the who classification.
boolean
C1334634 (UMLS CUI [1,1])
C1301142 (UMLS CUI [1,2])
C0006413 (UMLS CUI [2])
C1629504 (UMLS CUI [3])
C0079744 (UMLS CUI [4])
C1292754 (UMLS CUI [5])
C1334634 (UMLS CUI [6,1])
C1518425 (UMLS CUI [6,2])
Study Subject untreated | Steroids Duration | Emergency Therapeutic radiology procedure Duration
Item
2. participant must be previously untreated, (no more than 72 hours of steroids and/or emergency radiation)
boolean
C0681850 (UMLS CUI [1,1])
C0332155 (UMLS CUI [1,2])
C0038317 (UMLS CUI [2,1])
C0449238 (UMLS CUI [2,2])
C0013956 (UMLS CUI [3,1])
C1522449 (UMLS CUI [3,2])
C0449238 (UMLS CUI [3,3])
Age
Item
3. participant must be < 22 years of age at the time of diagnosis
boolean
C0001779 (UMLS CUI [1])
Mediastinal (Thymic) Large B-Cell Lymphoma | rituximab | Viral hepatitis screening test | Hepatitis B carrier Rituximab Excluded
Item
4. for group b participants with mediastinal large b cell lymphoma (mlbcl) disease only (receiving rituximab) - all participants with mlbcl assigned to group b must have hepatitis screening prior to enrollment. participants whose results indicate that they are carrier of hepatitis b can still be treated per group b but will not receive rituximab. this screening must be done for eligibility but the results are not needed prior to enrollment:
boolean
C1292754 (UMLS CUI [1])
C0393022 (UMLS CUI [2])
C1445958 (UMLS CUI [3])
C0262505 (UMLS CUI [4,1])
C0393022 (UMLS CUI [4,2])
C0332196 (UMLS CUI [4,3])
Hepatitis B Immunization status | Vaccination
Item
hepatitis b immunization status (vaccination yes or no)
boolean
C0019163 (UMLS CUI [1,1])
C0552506 (UMLS CUI [1,2])
C0042196 (UMLS CUI [2])
Hepatitis B Surface Antigens
Item
hbsag
boolean
C0019168 (UMLS CUI [1])
Anti-HBs antibody
Item
anti-hbs antibody
boolean
C0201478 (UMLS CUI [1])
Anti-HBc antibody | Hepatitis B carrier Rituximab Excluded
Item
anti-hbc antibody. all participants must have screening prior to enrollment. participants whose results indicate that they are carrier of hepatitis b can still be treated per group b but will not receive rituximab.
boolean
C0948759 (UMLS CUI [1])
C0262505 (UMLS CUI [2,1])
C0393022 (UMLS CUI [2,2])
C0332196 (UMLS CUI [2,3])
Human immunodeficiency virus test | HIV Seropositivity Study Therapeutic Excluded
Item
5. hiv test has been obtained within 42 days. participants who test positive for hiv cannot be enrolled on therapeutic part of study, but are still eligible for biology studies.
boolean
C1321876 (UMLS CUI [1])
C0019699 (UMLS CUI [2,1])
C2603343 (UMLS CUI [2,2])
C0302350 (UMLS CUI [2,3])
C0332196 (UMLS CUI [2,4])
Informed Consent
Item
6. informed consent must be obtained according to st. jude guidelines before enrollment into study
boolean
C0021430 (UMLS CUI [1])
Collaboration Study Site | Objective biological
Item
participants from collaborating sites participating in biological objectives only:
boolean
C0282116 (UMLS CUI [1,1])
C2825164 (UMLS CUI [1,2])
C0018017 (UMLS CUI [2,1])
C0205460 (UMLS CUI [2,2])
Mature B-Cell Lymphoma WHO tumor classification | Burkitt Lymphoma | Atypical Burkitt's lymphoma | Diffuse Large B-Cell Lymphoma | Mediastinal (Thymic) Large B-Cell Lymphoma | Mature B-Cell Lymphoma NOS
Item
1. participant must have a histologic diagnosis of a mature b cell lymphoma (e.g., burkitt lymphoma/leukemia, atypical burkitt lymphoma, diffuse large b-cell lymphoma, mediastinal large b-cell lymphoma, mature b-cell lymphoma nos) as defined in the who classification
boolean
C1334634 (UMLS CUI [1,1])
C1301142 (UMLS CUI [1,2])
C0006413 (UMLS CUI [2])
C1629504 (UMLS CUI [3])
C0079744 (UMLS CUI [4])
C1292754 (UMLS CUI [5])
C1334634 (UMLS CUI [6,1])
C1518425 (UMLS CUI [6,2])
Age
Item
2. participant must be < 22 years of age at the time of diagnosis
boolean
C0001779 (UMLS CUI [1])
Informed Consent
Item
3. informed consent must be obtained by local pi or his/her designee according to ich/good clinical practice and local guidelines before enrollment into study
boolean
C0021430 (UMLS CUI [1])
Collaboration Study Site | Objective Therapeutic | Objective biological
Item
participants from collaborating sites participating in therapeutic and biological objectives:
boolean
C0282116 (UMLS CUI [1,1])
C2825164 (UMLS CUI [1,2])
C0018017 (UMLS CUI [2,1])
C0302350 (UMLS CUI [2,2])
C0018017 (UMLS CUI [3,1])
C0205460 (UMLS CUI [3,2])
Prior Therapy | Exception Steroids | Exception Therapeutic radiology procedure
Item
1. participants with prior therapy (except steroids or rt)
boolean
C1514463 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0038317 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C1522449 (UMLS CUI [3,2])
HIV Seropositivity
Item
2. participants known to be hiv positive (for therapeutic part of protocol, hiv participants are eligible for biology studies).
boolean
C0019699 (UMLS CUI [1])
Pregnancy | Breast Feeding
Item
3. participants who are pregnant or lactating
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Informed Consent Unable | Informed Consent Unwilling | Legal Guardian Informed Consent Unable | Legal Guardian Informed Consent Unwilling
Item
4. inability or unwillingness of research participant or legal guardian to consent
boolean
C0021430 (UMLS CUI [1,1])
C1299582 (UMLS CUI [1,2])
C0021430 (UMLS CUI [2,1])
C0558080 (UMLS CUI [2,2])
C0023226 (UMLS CUI [3,1])
C0021430 (UMLS CUI [3,2])
C1299582 (UMLS CUI [3,3])
C0023226 (UMLS CUI [4,1])
C0021430 (UMLS CUI [4,2])
C0558080 (UMLS CUI [4,3])
Emergency Steroids | Emergency Therapeutic radiology procedure | Study biological Excluded
Item
5. participants who received emergent steroids and/or radiation prior to biopsy may be included in therapeutic part of study, but will be excluded from biology studies.
boolean
C0013956 (UMLS CUI [1,1])
C0038317 (UMLS CUI [1,2])
C0013956 (UMLS CUI [2,1])
C1522449 (UMLS CUI [2,2])
C2603343 (UMLS CUI [3,1])
C0205460 (UMLS CUI [3,2])
C0332196 (UMLS CUI [3,3])
Collaboration Study Site | Objective biological
Item
participants from collaborating sites participating in biological objectives only:
boolean
C0282116 (UMLS CUI [1,1])
C2825164 (UMLS CUI [1,2])
C0018017 (UMLS CUI [2,1])
C0205460 (UMLS CUI [2,2])
Informed Consent Unable | Informed Consent Unwilling | Legal Guardian Informed Consent Unable | Legal Guardian Informed Consent Unwilling
Item
1. inability or unwillingness of research participant or legal guardian to consent
boolean
C0021430 (UMLS CUI [1,1])
C1299582 (UMLS CUI [1,2])
C0021430 (UMLS CUI [2,1])
C0558080 (UMLS CUI [2,2])
C0023226 (UMLS CUI [3,1])
C0021430 (UMLS CUI [3,2])
C1299582 (UMLS CUI [3,3])
C0023226 (UMLS CUI [4,1])
C0021430 (UMLS CUI [4,2])
C0558080 (UMLS CUI [4,3])
Histological diagnosis WHO classification | Exception Mature B-Cell Lymphoma
Item
2. histologic diagnosis other than a mature b-cell lymphoma as defined in the who classification
boolean
C0679557 (UMLS CUI [1,1])
C4267671 (UMLS CUI [1,2])
C1705847 (UMLS CUI [2,1])
C1334634 (UMLS CUI [2,2])
Emergency Steroids | Emergency Therapeutic radiology procedure
Item
3. participants who received emergent steroids and/or radiation prior to biopsy
boolean
C0013956 (UMLS CUI [1,1])
C0038317 (UMLS CUI [1,2])
C0013956 (UMLS CUI [2,1])
C1522449 (UMLS CUI [2,2])